AstraZeneca Inventory 2010-2024 | AZN

AstraZeneca inventory from 2010 to 2024. Inventory can be defined as the total value of inventories in all stages of completion.
  • AstraZeneca inventory for the quarter ending June 30, 2024 was $5.667B, a 12.2% increase year-over-year.
  • AstraZeneca inventory for 2023 was $5.424B, a 15.43% increase from 2022.
  • AstraZeneca inventory for 2022 was $4.699B, a 47.69% decline from 2021.
  • AstraZeneca inventory for 2021 was $8.983B, a 123.24% increase from 2020.
AstraZeneca Annual Inventory
(Millions of US $)
2023 $5,424
2022 $4,699
2021 $8,983
2020 $4,024
2019 $3,193
2018 $2,890
2017 $3,035
2016 $2,334
2015 $2,143
2014 $1,960
2013 $1,909
2012 $2,061
2011 $1,852
2010 $1,682
2009 $1,750
AstraZeneca Quarterly Inventory
(Millions of US $)
2024-06-30 $5,667
2024-03-31 $5,337
2023-12-31 $5,424
2023-09-30 $5,292
2023-06-30 $5,051
2023-03-31 $4,967
2022-12-31 $4,699
2022-09-30 $5,078
2022-06-30 $6,220
2022-03-31 $7,624
2021-12-31 $8,983
2021-09-30 $10,528
2021-06-30 $4,762
2021-03-31 $4,278
2020-12-31 $4,024
2020-09-30 $3,683
2020-06-30 $3,562
2020-03-31 $3,123
2019-12-31 $3,193
2019-09-30 $3,129
2019-06-30 $3,197
2019-03-31 $3,050
2018-12-31 $2,890
2018-09-30 $3,027
2018-06-30 $3,118
2018-03-31 $3,283
2017-12-31 $3,035
2017-09-30 $3,162
2017-06-30 $2,901
2017-03-31 $2,652
2016-12-31 $2,334
2016-09-30 $2,420
2016-06-30 $2,422
2016-03-31 $2,344
2015-12-31 $2,143
2015-09-30 $2,193
2015-06-30 $2,198
2015-03-31 $1,968
2014-12-31 $1,960
2014-09-30 $1,957
2014-06-30 $2,249
2014-03-31 $2,163
2013-12-31 $1,909
2013-09-30 $2,075
2013-06-30 $2,089
2013-03-31 $2,039
2012-12-31 $2,061
2012-09-30 $2,090
2012-06-30 $2,039
2012-03-31 $2,040
2011-12-31 $1,852
2011-09-30 $1,955
2011-06-30 $2,021
2011-03-31 $1,897
2010-12-31 $1,682
2010-09-30 $1,810
2010-06-30 $1,689
2010-03-31 $1,780
2009-12-31 $1,750
2009-09-30 $1,898
2009-06-30 $1,866
2009-03-31 $1,702
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $199.957B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51